WO2004002425A3 - Process for promoting graft acceptance by depletion of hematopoietic stem cells - Google Patents

Process for promoting graft acceptance by depletion of hematopoietic stem cells Download PDF

Info

Publication number
WO2004002425A3
WO2004002425A3 PCT/US2003/020520 US0320520W WO2004002425A3 WO 2004002425 A3 WO2004002425 A3 WO 2004002425A3 US 0320520 W US0320520 W US 0320520W WO 2004002425 A3 WO2004002425 A3 WO 2004002425A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
hematopoietic stem
depletion
depleting
inactivating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/020520
Other languages
French (fr)
Other versions
WO2004002425A2 (en
Inventor
Julian D Down
Mary E White-Scharf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotransplant Inc
Original Assignee
Biotransplant Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotransplant Inc filed Critical Biotransplant Inc
Priority to AU2003245752A priority Critical patent/AU2003245752A1/en
Publication of WO2004002425A2 publication Critical patent/WO2004002425A2/en
Publication of WO2004002425A3 publication Critical patent/WO2004002425A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Therapeutic compositions and methods for modulating the immune system for promoting acceptance of a graft and for treating a hematologic malignancy in the absence of myeloablative therapies are disclosed. The described methodology includes the step of depleting and/or inactivating the hematopoietic stem cells of the recipient using a therapeutic composition comprising at least one antibody specific for depleting and/or inactivating hematopoietic stem cells while maintaining mature blood cells, preferably the antibody selectively depletes and/or inactivates primitive hematopoietic stem cells. The therapeutic composition preferably is administered prior to the administration of bone marrow, mobilized peripheral hematopoietic stem cells, or donor leucocytes.
PCT/US2003/020520 2002-06-28 2003-06-27 Process for promoting graft acceptance by depletion of hematopoietic stem cells Ceased WO2004002425A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003245752A AU2003245752A1 (en) 2002-06-28 2003-06-27 Process for promoting graft acceptance by depletion of hematopoietic stem cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39259002P 2002-06-28 2002-06-28
US60/392,590 2002-06-28
US35770603A 2003-02-04 2003-02-04
US10/357,706 2003-02-04

Publications (2)

Publication Number Publication Date
WO2004002425A2 WO2004002425A2 (en) 2004-01-08
WO2004002425A3 true WO2004002425A3 (en) 2004-08-26

Family

ID=30002887

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/020520 Ceased WO2004002425A2 (en) 2002-06-28 2003-06-27 Process for promoting graft acceptance by depletion of hematopoietic stem cells

Country Status (2)

Country Link
AU (1) AU2003245752A1 (en)
WO (1) WO2004002425A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3255061B1 (en) * 2006-11-03 2021-06-16 The Board of Trustees of the Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
EP2349224B1 (en) 2008-10-10 2017-05-10 Probelte Pharma, S.A. Orally administrable immunostimulant product for aquaculture
JP5688734B2 (en) * 2008-12-12 2015-03-25 国立大学法人 東京大学 Immunological reconstruction promoter or infection preventive agent that preserves graft versus tumor effect
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2015050959A1 (en) * 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
JP6768639B2 (en) 2014-05-23 2020-10-21 セルデックス セラピューティクス，インコーポレーテッド Treatment of eosinophil or mast cell related disorders
US20170209447A1 (en) * 2014-08-07 2017-07-27 Nitor Therapeutics Use of PNP Inhibitor to Treat Relapse of Malignancy after Hematopoietic Stem Cell Transplant
ES2945588T3 (en) 2014-08-26 2023-07-04 Univ Leland Stanford Junior Stem cell engraftment with a combination of a stem cell-targeted agent and modulation of immunoregulatory signaling
HK1256681A1 (en) 2015-04-06 2019-10-04 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
ES2894335T5 (en) 2015-08-26 2024-06-27 Univ Leland Stanford Junior Enhanced Target Cell Depletion with CD47 Blockade and an Immune Costimulatory Agonist
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
CN117653740A (en) * 2016-12-21 2024-03-08 诺华股份有限公司 Antibody drug conjugates for ablating hematopoietic stem cells
IL301075B2 (en) 2017-01-30 2024-05-01 Univ Leland Stanford Junior A non-genotoxic conditioning regimen for stem cell transplantation
US12485186B2 (en) 2017-03-31 2025-12-02 The Children's Medical Center Corporation Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
UY38265A (en) * 2018-06-20 2020-01-31 Novartis Ag DRUG ANTIBODY CONJUGATES FOR ABLATION OF HEMATOPOIETIC STEM CELLS
KR20210094609A (en) 2018-11-28 2021-07-29 포티 세븐, 인코포레이티드 Genetically Modified HSPCs Resistant to Ablation Regimes
EP3958879A4 (en) * 2019-04-25 2023-05-10 Actinium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR IMMUNE DEPLETION FOR THE TREATMENT OF MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISEASES
EP4611807A4 (en) * 2022-11-04 2026-07-29 Univ Leland Stanford Junior Rebalancing of the immune system through depletion of myeloid-precise hematopoietic stem cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007444A1 (en) * 1996-08-16 1998-02-26 Biotransplant, Inc. LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION
WO2001025398A2 (en) * 1999-10-01 2001-04-12 Biotransplant Incorporated Process for inducing functional tolerance to gene transfer products
WO2001030369A1 (en) * 1999-10-22 2001-05-03 Biotransplant, Inc. Process for inducing immunological tolerance for xenogeneic transplants
WO2001087310A1 (en) * 2000-05-18 2001-11-22 Biotransplant, Inc. Process for reducing antibody response against xenografts
WO2002033043A2 (en) * 2000-10-18 2002-04-25 Coriell Institute For Medical Research Method and marker for the isolation of human multipotent hematopoietic stem cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007444A1 (en) * 1996-08-16 1998-02-26 Biotransplant, Inc. LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION
WO2001025398A2 (en) * 1999-10-01 2001-04-12 Biotransplant Incorporated Process for inducing functional tolerance to gene transfer products
WO2001030369A1 (en) * 1999-10-22 2001-05-03 Biotransplant, Inc. Process for inducing immunological tolerance for xenogeneic transplants
WO2001087310A1 (en) * 2000-05-18 2001-11-22 Biotransplant, Inc. Process for reducing antibody response against xenografts
WO2002033043A2 (en) * 2000-10-18 2002-04-25 Coriell Institute For Medical Research Method and marker for the isolation of human multipotent hematopoietic stem cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUHLER L. ET AL: "High-dose porcine hematopoietic cell transplantation combined with CD40 ligand blockade in baboons prevents an induced anti-pig humoral response", TRANSPLANTATION, vol. 69, no. 11, 15 June 2000 (2000-06-15), pages 2296 - 2304, XP002978334 *
BUHLER L. ET AL: "Pig hematopoietic cell chimerism in baboons conditioned with a nonmyeloablative regimen and CD154 blockade", TRANSPLANTATION, vol. 73, no. 1, 15 January 2002 (2002-01-15), pages 12 - 22, XP002978708 *
GIOVINO MA ET AL: "Porcine hematopoiesis on primate stroma in long-term cultures: enhanced growth with neutralizing tumor necrosis factor-alpha and tumor growth factor-beta antibodies", TRANSPLANTATION, vol. 73, no. 5, 15 March 2002 (2002-03-15), pages 723 - 731, XP002978373 *

Also Published As

Publication number Publication date
AU2003245752A8 (en) 2004-01-19
WO2004002425A2 (en) 2004-01-08
AU2003245752A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
Carlson et al. Platelet-rich plasma: clinical applications in dentistry
Kitoh et al. Transplantation of marrow-derived mesenchymal stem cells and platelet-rich plasma during distraction osteogenesis—a preliminary result of three cases
Kawasumi et al. The effect of the platelet concentration in platelet-rich plasma gel on the regeneration of bone
Connolly Injectable bone marrow preparations to stimulate osteogenic repair
AU697761B2 (en) Decontaminating blood components with 8-methoxypsoralen
Smrke et al. Treatment of bone defects—allogenic platelet gel and autologous bone technique
DE60038884D1 (en) Autologes thrombin
WO2004094619A3 (en) Hematopoietic stem cells treated by in vitro fucosylation and methods of use
DE69922362D1 (en) METHOD FOR THE PREPARATION OF A DIAFILTRATED STABLE BLOOD PRODUCT
GB0001309D0 (en) Valve arrangement
De Fabritiis et al. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement
WO1999003976A3 (en) Method of treating leukocytes, leukocyte compositions and methods of use thereof
EP1491093A3 (en) Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
AU5459199A (en) Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
WO2000040269A3 (en) Pharmaceutical compositions for treatment of diseased tissues
NO20060498L (en) Method of promoting bone growth
IL144523A0 (en) Method and compositions for healing and repair of articular cartilage
HUS1900041I1 (en) Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation
EP0953351A3 (en) Medicaments containing, as the main ingredient, allogenic activated-CD4+ cells and method for producing the same
ATE442434T1 (en) METHOD FOR SUPPRESSING AN IMMUNE SYSTEM REACTION AGAINST TISSUE OR CELL TRANSPLANTS
WO2001094586A3 (en) Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
EP1890713B1 (en) Osteoblast composition of semi-solidified mixed fibrin for bone fracture agglutination and its manufacturing method
Couban et al. The source of cells for allografting
MXPA02011592A (en) Human circulating dendritic cell compositions and methods.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP